Gynecologic Cancer News

September is Gynecologic Cancer Awareness Month, an awareness campaign launched by the Foundation for Women’s Cancer.

Survivors of most types of cancers demonstrated increased medium- to long-term risk for at least one cardiovascular disease compared with the general population, according to results of a retrospective study published in The Lancet.

CDC data showed that most of the estimated 34,800 cancers yearly attributed to HPV annually between 2012 and 2016 could have been prevented if the patient had received the 9-valent HPV vaccine.

The U.S. Preventive Services Task Force recommends that primary care physicians assess women with a familial risk assessment tool if they have family history of breast, ovarian, tubal or peritoneal cancer, or if they have an ancestry associated with BRCA1 or BRCA2 mutations.

Biotech firm Phio Pharmaceuticals announced it has entered into a research collaboration with Helmholtz Zentrum München, the German Research Center for Environmental Health, to develop T cell and natural killer cell adoptive cell therapies for the treatment of solid tumors.

There will be 22,530 new cases of ovarian cancer in the United States this year.

Women with cervical cancer who experienced psychiatric disorders and stress around the time of diagnosis demonstrated higher rates of cancer-specific mortality than women without such distress at diagnosis, according to study results published in Cancer Research.

Cell-free DNA fragmentation profiles could be used for screening, early detection and monitoring of certain cancer types, study findings suggest.

Chemoradiotherapy significantly improved OS and failure-free survival compared with pelvic radiotherapy alone among women with high-risk endometrial cancer, according to results from the PORTEC-3 randomized phase 3 trial published in The Lancet Oncology.

Ovarian Cancer Research Alliance presented its Rosalind Franklin Prize for Excellence in Ovarian Cancer Research to Kunle Odunsi, MD, PhD, FRCOG, FACOG.